8/102 sources · 2 publishersUpdated Oct 17, 11:05 UTC
Johnson & Johnson posts Q3 earnings beat, raises sales outlook but shares drop on MedTech weakness
Johnson & Johnson reported third‑quarter adjusted earnings of $2.59 per share on revenue of $25.9 billion. Management lifted its full‑year operational sales‑growth guidance and kept free cash flow near $21 billion, while noting a slowdown in its medical‑technology segment. The earnings beat was followed by a roughly 6% decline in the stock as investors reacted to the MedTech shortfall.
Why it matters
The raised sales guidance could support higher future earnings, but the share‑price drop reflects investor concern over the MedTech division, which may affect short‑term valuation.
Key facts
- 1Adjusted EPS for Q3 was $2.59, beating estimates. investing.com
- 2Quarterly revenue was $25.9 billion. finance.yahoo.com
- 3Free cash flow was maintained at roughly $21 billion. investing.com
- 4MedTech revenue grew 2.5% to $8.6 billion, below analyst expectations. finance.yahoo.com
- 5Oncology sales rose 16% YoY to $7.6 billion. finance.yahoo.com
- 6The stock fell nearly 6% after the earnings release. finance.yahoo.com
Open questions
- Material 1 states operational sales‑growth guidance of 6.7%–7.1%, while material 2 gives a range of 6.4%–6.8% for the same metric.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.